Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

599 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the "RAMP" Italian multicenter prospective study.
Palandri F, Auteri G, Abruzzese E, Caocci G, Bonifacio M, Mendicino F, Latagliata R, Iurlo A, Branzanti F, Garibaldi B, Trawinska MM, Cattaneo D, Krampera M, Mulas O, Martino EA, Cavo M, Vianelli N, Impera S, Efficace F, Heidel F, Breccia M, Elli EM, Palumbo GA. Palandri F, et al. Among authors: breccia m. Ann Hematol. 2024 Jun;103(6):1931-1940. doi: 10.1007/s00277-024-05704-0. Epub 2024 Mar 13. Ann Hematol. 2024. PMID: 38478023 Free PMC article. Clinical Trial.
Conservative treatment for patients over 80 years with acute myelogenous leukemia.
Latagliata R, Alimena G, Carmosino I, Breccia M, Borza PA, Bongarzoni V, Copia C, Spadea A, Pinazzi B, Frattarelli N, Ferrara F, Petti MC, Mandelli F. Latagliata R, et al. Among authors: breccia m. Am J Hematol. 2002 Dec;71(4):256-9. doi: 10.1002/ajh.10235. Am J Hematol. 2002. PMID: 12447953 Free article.
Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML.
Palandri F, Iacobucci I, Martinelli G, Amabile M, Poerio A, Testoni N, Soverini S, Castagnetti F, De Vivo A, Breccia M, Specchia G, Abruzzese E, Martino B, Cilloni D, Saglio G, Pane F, Liberati AM, Rosti G, Baccarani M; GIMEMA Working Party on CML. Palandri F, et al. Among authors: breccia m. J Clin Oncol. 2008 Jan 1;26(1):106-11. doi: 10.1200/JCO.2007.13.2373. J Clin Oncol. 2008. PMID: 18165644
Hammersmith score application identifies chronic myeloid leukemia patients with poor prognosis before treatment with second-generation tyrosine kinase inhibitors.
Breccia M, Stagno F, Gozzini A, Abruzzese E, Latagliata R, Rossi AR, Sorà F, Porrini R, Vigneri P, Trawinska M, Montefusco E, Sica S, Specchia G, Santini V, Alimena G. Breccia M, et al. Am J Hematol. 2011 Jun;86(6):523-5. doi: 10.1002/ajh.22020. Am J Hematol. 2011. PMID: 21594891 Free article. No abstract available.
Low incidence rate of opportunistic and viral infections during imatinib treatment in chronic myeloid leukemia patients in early and late chronic phase.
Breccia M, Girmenia C, Latagliata R, Loglisci G, Santopietro M, Federico V, Petrucci L, Serrao A, Salaroli A, Alimena G. Breccia M, et al. Mediterr J Hematol Infect Dis. 2011;3(1):e2011021. doi: 10.4084/MJHID.2011.021. Epub 2011 May 16. Mediterr J Hematol Infect Dis. 2011. PMID: 21713076 Free PMC article.
Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals? GIMEMA and EORTC Quality of Life Group.
Efficace F, Breccia M, Saussele S, Kossak-Roth U, Cardoni A, Caocci G, Chie W, Naeem A, Nicolatou-Galitis O, Cocks K, Vignetti M, Baccarani M, Mandelli F, Sprangers M. Efficace F, et al. Among authors: breccia m. Ann Hematol. 2012 Sep;91(9):1371-81. doi: 10.1007/s00277-012-1458-6. Epub 2012 Apr 29. Ann Hematol. 2012. PMID: 22543826
599 results